Every year, cardiometabolic diseases cause tens of millions of deaths, despite the hundreds of billions of euros generated in health expenditure. These diseases are mainly caused by an “imbalanced” lifestyle, which encourages excessive calorie intake, a diet too high in fat and/or sugar, often combined with a lack of physical and sporting activity.

Diabetes, NASH (non-alcoholic steatohepatitis), Obesity and Dyslipidemia are conditions or disorders which require prevention on a global scale. For example, the International Diabetes Federation estimates that the number of diabetics was 415 million in 2015, of which 90% had type 2 diabetes, which is mainly lifestyle-related. These figures are alarming since they are expected to climb to 642 million in 2040. In 2015 alone, close to 673 billion dollars were spent on this disease by healthcare systems.

This is why VALBIOTIS wishes to provide solid solutions designed to prevent risk factors and conditions for developing cardiometabolic diseases, in addition to solutions designed to provide nutritional support for patients and for everyone’s health and well-being.

Our scientific approach

Cardiometabolic diseases are complex conditions that involve more than tissue or receptor dysfunction. They affect several organs. One of the benefits of plants is that they are composed of a multitude of molecules, which allow for “multi-targeted” action to meet the challenges created by complex health conditions. The plant’s totum (total composition) contains all the plant’s active molecules. VALBIOTIS uses this totum to develop new-generation innovative products.

VAL-LAB platform